Biomimetic cardiovascular platforms for in vitro disease modeling and therapeutic validation
Bioengineered tissues have become increasingly more sophisticated owing to recent advancements in the fields of biomaterials, microfabrication, microfluidics, genetic engineering, and stem cell and developmental biology. In the coming years, the ability to engineer artificial constructs that accurat...
Gespeichert in:
Veröffentlicht in: | Biomaterials 2019-04, Vol.198, p.78-94 |
---|---|
Hauptverfasser: | , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 94 |
---|---|
container_issue | |
container_start_page | 78 |
container_title | Biomaterials |
container_volume | 198 |
creator | Portillo-Lara, Roberto Spencer, Andrew R. Walker, Brian W. Shirzaei Sani, Ehsan Annabi, Nasim |
description | Bioengineered tissues have become increasingly more sophisticated owing to recent advancements in the fields of biomaterials, microfabrication, microfluidics, genetic engineering, and stem cell and developmental biology. In the coming years, the ability to engineer artificial constructs that accurately mimic the compositional, architectural, and functional properties of human tissues, will profoundly impact the therapeutic and diagnostic aspects of the healthcare industry. In this regard, bioengineered cardiac tissues are of particular importance due to the extremely limited ability of the myocardium to self-regenerate, as well as the remarkably high mortality associated with cardiovascular diseases worldwide. As novel microphysiological systems make the transition from bench to bedside, their implementation in high throughput drug screening, personalized diagnostics, disease modeling, and targeted therapy validation will bring forth a paradigm shift in the clinical management of cardiovascular diseases. Here, we will review the current state of the art in experimental in vitro platforms for next generation diagnostics and therapy validation. We will describe recent advancements in the development of smart biomaterials, biofabrication techniques, and stem cell engineering, aimed at recapitulating cardiovascular function at the tissue- and organ levels. In addition, integrative and multidisciplinary approaches to engineer biomimetic cardiovascular constructs with unprecedented human and clinical relevance will be discussed. We will comment on the implementation of these platforms in high throughput drug screening, in vitro disease modeling and therapy validation. Lastly, future perspectives will be provided on how these biomimetic platforms will aid in the transition towards patient centered diagnostics, and the development of personalized targeted therapeutics. |
doi_str_mv | 10.1016/j.biomaterials.2018.08.010 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11044891</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0142961218305647</els_id><sourcerecordid>2102338811</sourcerecordid><originalsourceid>FETCH-LOGICAL-c554t-621ef192b05667dd341cc6647ef7c8ce9b9a9ac74b22e5bf302048f81cbfe2db3</originalsourceid><addsrcrecordid>eNqNUV1rFTEQDaLYa_UvSPDJl71msl9ZX8RWW4WCL_omhGwy285ld3NNsgv-e7PcWuqbMCQMc86ZwxzG3oDYg4Dm3WHfk59MwkBmjHspQO1FLhBP2A5Uq4q6E_VTthNQyaJrQJ6xFzEeRO5FJZ-zs1JkUi3kjv28yFI0YSLLrQmO_GqiXUYT-HE0afBhijy_nGa-UgqeO4poIvLJOxxpvuVmdjzdYTBHXDaZ1YzkTCI_v2TPhuwQX93_5-zH1efvl1-Km2_XXy8_3hS2rqtUNBJwgE72om6a1rmyAmubpmpxaK2y2PWd6Yxtq15KrPthc1-pQYHtB5SuL8_Zh5PucekndBbnFMyoj4EmE35rb0j_O5npTt_6VQOIqlIdZIW39wrB_1owJj1RtDiOZka_RC1ByLJUCjbo-xPUBh9jwOFhDwi95aMP-nE-estHi1wgMvn1Y6cP1L-BZMCnEwDzvVbCoKMlnC06CmiTdp7-Z88fZnOsEQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2102338811</pqid></control><display><type>article</type><title>Biomimetic cardiovascular platforms for in vitro disease modeling and therapeutic validation</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Portillo-Lara, Roberto ; Spencer, Andrew R. ; Walker, Brian W. ; Shirzaei Sani, Ehsan ; Annabi, Nasim</creator><creatorcontrib>Portillo-Lara, Roberto ; Spencer, Andrew R. ; Walker, Brian W. ; Shirzaei Sani, Ehsan ; Annabi, Nasim</creatorcontrib><description>Bioengineered tissues have become increasingly more sophisticated owing to recent advancements in the fields of biomaterials, microfabrication, microfluidics, genetic engineering, and stem cell and developmental biology. In the coming years, the ability to engineer artificial constructs that accurately mimic the compositional, architectural, and functional properties of human tissues, will profoundly impact the therapeutic and diagnostic aspects of the healthcare industry. In this regard, bioengineered cardiac tissues are of particular importance due to the extremely limited ability of the myocardium to self-regenerate, as well as the remarkably high mortality associated with cardiovascular diseases worldwide. As novel microphysiological systems make the transition from bench to bedside, their implementation in high throughput drug screening, personalized diagnostics, disease modeling, and targeted therapy validation will bring forth a paradigm shift in the clinical management of cardiovascular diseases. Here, we will review the current state of the art in experimental in vitro platforms for next generation diagnostics and therapy validation. We will describe recent advancements in the development of smart biomaterials, biofabrication techniques, and stem cell engineering, aimed at recapitulating cardiovascular function at the tissue- and organ levels. In addition, integrative and multidisciplinary approaches to engineer biomimetic cardiovascular constructs with unprecedented human and clinical relevance will be discussed. We will comment on the implementation of these platforms in high throughput drug screening, in vitro disease modeling and therapy validation. Lastly, future perspectives will be provided on how these biomimetic platforms will aid in the transition towards patient centered diagnostics, and the development of personalized targeted therapeutics.</description><identifier>ISSN: 0142-9612</identifier><identifier>EISSN: 1878-5905</identifier><identifier>DOI: 10.1016/j.biomaterials.2018.08.010</identifier><identifier>PMID: 30201502</identifier><language>eng</language><publisher>Netherlands: Elsevier Ltd</publisher><subject>Animals ; Biocompatible Materials - chemistry ; Bioengineering - instrumentation ; Bioengineering - methods ; Biomimetics - instrumentation ; Biomimetics - methods ; Cardiovascular Diseases - diagnosis ; Cardiovascular Diseases - drug therapy ; Cardiovascular Diseases - pathology ; Drug Discovery - instrumentation ; Drug Discovery - methods ; Drug Evaluation, Preclinical - instrumentation ; Drug Evaluation, Preclinical - methods ; Equipment Design ; Humans ; Lab-On-A-Chip Devices</subject><ispartof>Biomaterials, 2019-04, Vol.198, p.78-94</ispartof><rights>2018 Elsevier Ltd</rights><rights>Copyright © 2018 Elsevier Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c554t-621ef192b05667dd341cc6647ef7c8ce9b9a9ac74b22e5bf302048f81cbfe2db3</citedby><cites>FETCH-LOGICAL-c554t-621ef192b05667dd341cc6647ef7c8ce9b9a9ac74b22e5bf302048f81cbfe2db3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.biomaterials.2018.08.010$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,780,784,885,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30201502$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Portillo-Lara, Roberto</creatorcontrib><creatorcontrib>Spencer, Andrew R.</creatorcontrib><creatorcontrib>Walker, Brian W.</creatorcontrib><creatorcontrib>Shirzaei Sani, Ehsan</creatorcontrib><creatorcontrib>Annabi, Nasim</creatorcontrib><title>Biomimetic cardiovascular platforms for in vitro disease modeling and therapeutic validation</title><title>Biomaterials</title><addtitle>Biomaterials</addtitle><description>Bioengineered tissues have become increasingly more sophisticated owing to recent advancements in the fields of biomaterials, microfabrication, microfluidics, genetic engineering, and stem cell and developmental biology. In the coming years, the ability to engineer artificial constructs that accurately mimic the compositional, architectural, and functional properties of human tissues, will profoundly impact the therapeutic and diagnostic aspects of the healthcare industry. In this regard, bioengineered cardiac tissues are of particular importance due to the extremely limited ability of the myocardium to self-regenerate, as well as the remarkably high mortality associated with cardiovascular diseases worldwide. As novel microphysiological systems make the transition from bench to bedside, their implementation in high throughput drug screening, personalized diagnostics, disease modeling, and targeted therapy validation will bring forth a paradigm shift in the clinical management of cardiovascular diseases. Here, we will review the current state of the art in experimental in vitro platforms for next generation diagnostics and therapy validation. We will describe recent advancements in the development of smart biomaterials, biofabrication techniques, and stem cell engineering, aimed at recapitulating cardiovascular function at the tissue- and organ levels. In addition, integrative and multidisciplinary approaches to engineer biomimetic cardiovascular constructs with unprecedented human and clinical relevance will be discussed. We will comment on the implementation of these platforms in high throughput drug screening, in vitro disease modeling and therapy validation. Lastly, future perspectives will be provided on how these biomimetic platforms will aid in the transition towards patient centered diagnostics, and the development of personalized targeted therapeutics.</description><subject>Animals</subject><subject>Biocompatible Materials - chemistry</subject><subject>Bioengineering - instrumentation</subject><subject>Bioengineering - methods</subject><subject>Biomimetics - instrumentation</subject><subject>Biomimetics - methods</subject><subject>Cardiovascular Diseases - diagnosis</subject><subject>Cardiovascular Diseases - drug therapy</subject><subject>Cardiovascular Diseases - pathology</subject><subject>Drug Discovery - instrumentation</subject><subject>Drug Discovery - methods</subject><subject>Drug Evaluation, Preclinical - instrumentation</subject><subject>Drug Evaluation, Preclinical - methods</subject><subject>Equipment Design</subject><subject>Humans</subject><subject>Lab-On-A-Chip Devices</subject><issn>0142-9612</issn><issn>1878-5905</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNUV1rFTEQDaLYa_UvSPDJl71msl9ZX8RWW4WCL_omhGwy285ld3NNsgv-e7PcWuqbMCQMc86ZwxzG3oDYg4Dm3WHfk59MwkBmjHspQO1FLhBP2A5Uq4q6E_VTthNQyaJrQJ6xFzEeRO5FJZ-zs1JkUi3kjv28yFI0YSLLrQmO_GqiXUYT-HE0afBhijy_nGa-UgqeO4poIvLJOxxpvuVmdjzdYTBHXDaZ1YzkTCI_v2TPhuwQX93_5-zH1efvl1-Km2_XXy8_3hS2rqtUNBJwgE72om6a1rmyAmubpmpxaK2y2PWd6Yxtq15KrPthc1-pQYHtB5SuL8_Zh5PucekndBbnFMyoj4EmE35rb0j_O5npTt_6VQOIqlIdZIW39wrB_1owJj1RtDiOZka_RC1ByLJUCjbo-xPUBh9jwOFhDwi95aMP-nE-estHi1wgMvn1Y6cP1L-BZMCnEwDzvVbCoKMlnC06CmiTdp7-Z88fZnOsEQ</recordid><startdate>20190401</startdate><enddate>20190401</enddate><creator>Portillo-Lara, Roberto</creator><creator>Spencer, Andrew R.</creator><creator>Walker, Brian W.</creator><creator>Shirzaei Sani, Ehsan</creator><creator>Annabi, Nasim</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20190401</creationdate><title>Biomimetic cardiovascular platforms for in vitro disease modeling and therapeutic validation</title><author>Portillo-Lara, Roberto ; Spencer, Andrew R. ; Walker, Brian W. ; Shirzaei Sani, Ehsan ; Annabi, Nasim</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c554t-621ef192b05667dd341cc6647ef7c8ce9b9a9ac74b22e5bf302048f81cbfe2db3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Animals</topic><topic>Biocompatible Materials - chemistry</topic><topic>Bioengineering - instrumentation</topic><topic>Bioengineering - methods</topic><topic>Biomimetics - instrumentation</topic><topic>Biomimetics - methods</topic><topic>Cardiovascular Diseases - diagnosis</topic><topic>Cardiovascular Diseases - drug therapy</topic><topic>Cardiovascular Diseases - pathology</topic><topic>Drug Discovery - instrumentation</topic><topic>Drug Discovery - methods</topic><topic>Drug Evaluation, Preclinical - instrumentation</topic><topic>Drug Evaluation, Preclinical - methods</topic><topic>Equipment Design</topic><topic>Humans</topic><topic>Lab-On-A-Chip Devices</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Portillo-Lara, Roberto</creatorcontrib><creatorcontrib>Spencer, Andrew R.</creatorcontrib><creatorcontrib>Walker, Brian W.</creatorcontrib><creatorcontrib>Shirzaei Sani, Ehsan</creatorcontrib><creatorcontrib>Annabi, Nasim</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Biomaterials</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Portillo-Lara, Roberto</au><au>Spencer, Andrew R.</au><au>Walker, Brian W.</au><au>Shirzaei Sani, Ehsan</au><au>Annabi, Nasim</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Biomimetic cardiovascular platforms for in vitro disease modeling and therapeutic validation</atitle><jtitle>Biomaterials</jtitle><addtitle>Biomaterials</addtitle><date>2019-04-01</date><risdate>2019</risdate><volume>198</volume><spage>78</spage><epage>94</epage><pages>78-94</pages><issn>0142-9612</issn><eissn>1878-5905</eissn><abstract>Bioengineered tissues have become increasingly more sophisticated owing to recent advancements in the fields of biomaterials, microfabrication, microfluidics, genetic engineering, and stem cell and developmental biology. In the coming years, the ability to engineer artificial constructs that accurately mimic the compositional, architectural, and functional properties of human tissues, will profoundly impact the therapeutic and diagnostic aspects of the healthcare industry. In this regard, bioengineered cardiac tissues are of particular importance due to the extremely limited ability of the myocardium to self-regenerate, as well as the remarkably high mortality associated with cardiovascular diseases worldwide. As novel microphysiological systems make the transition from bench to bedside, their implementation in high throughput drug screening, personalized diagnostics, disease modeling, and targeted therapy validation will bring forth a paradigm shift in the clinical management of cardiovascular diseases. Here, we will review the current state of the art in experimental in vitro platforms for next generation diagnostics and therapy validation. We will describe recent advancements in the development of smart biomaterials, biofabrication techniques, and stem cell engineering, aimed at recapitulating cardiovascular function at the tissue- and organ levels. In addition, integrative and multidisciplinary approaches to engineer biomimetic cardiovascular constructs with unprecedented human and clinical relevance will be discussed. We will comment on the implementation of these platforms in high throughput drug screening, in vitro disease modeling and therapy validation. Lastly, future perspectives will be provided on how these biomimetic platforms will aid in the transition towards patient centered diagnostics, and the development of personalized targeted therapeutics.</abstract><cop>Netherlands</cop><pub>Elsevier Ltd</pub><pmid>30201502</pmid><doi>10.1016/j.biomaterials.2018.08.010</doi><tpages>17</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0142-9612 |
ispartof | Biomaterials, 2019-04, Vol.198, p.78-94 |
issn | 0142-9612 1878-5905 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11044891 |
source | MEDLINE; Access via ScienceDirect (Elsevier) |
subjects | Animals Biocompatible Materials - chemistry Bioengineering - instrumentation Bioengineering - methods Biomimetics - instrumentation Biomimetics - methods Cardiovascular Diseases - diagnosis Cardiovascular Diseases - drug therapy Cardiovascular Diseases - pathology Drug Discovery - instrumentation Drug Discovery - methods Drug Evaluation, Preclinical - instrumentation Drug Evaluation, Preclinical - methods Equipment Design Humans Lab-On-A-Chip Devices |
title | Biomimetic cardiovascular platforms for in vitro disease modeling and therapeutic validation |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T19%3A38%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Biomimetic%20cardiovascular%20platforms%20for%20in%20vitro%20disease%20modeling%20and%20therapeutic%20validation&rft.jtitle=Biomaterials&rft.au=Portillo-Lara,%20Roberto&rft.date=2019-04-01&rft.volume=198&rft.spage=78&rft.epage=94&rft.pages=78-94&rft.issn=0142-9612&rft.eissn=1878-5905&rft_id=info:doi/10.1016/j.biomaterials.2018.08.010&rft_dat=%3Cproquest_pubme%3E2102338811%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2102338811&rft_id=info:pmid/30201502&rft_els_id=S0142961218305647&rfr_iscdi=true |